TEMİ, Y. B. Et Al. 2024. Can the Prognosis be Predicted by the Pretreatment Derived Neutrophil to Lymphocyte Ratio (dNLR) in Patients with Castration-Resistant Prostate Cancer Receiving Enzalutamide?. Kocaeli Tıp Dergisi , vol.13, no.1 , 46-51.

TEMİ, Y. B., ŞAHİN, E., KEFELİ, U., ÇABUK, D., & UYGUN, K., (2024). Can the Prognosis be Predicted by the Pretreatment Derived Neutrophil to Lymphocyte Ratio (dNLR) in Patients with Castration-Resistant Prostate Cancer Receiving Enzalutamide?. Kocaeli Tıp Dergisi , vol.13, no.1, 46-51.

TEMİ, YASEMİN Et Al. "Can the Prognosis be Predicted by the Pretreatment Derived Neutrophil to Lymphocyte Ratio (dNLR) in Patients with Castration-Resistant Prostate Cancer Receiving Enzalutamide?," Kocaeli Tıp Dergisi , vol.13, no.1, 46-51, 2024

TEMİ, YASEMİN B. Et Al. "Can the Prognosis be Predicted by the Pretreatment Derived Neutrophil to Lymphocyte Ratio (dNLR) in Patients with Castration-Resistant Prostate Cancer Receiving Enzalutamide?." Kocaeli Tıp Dergisi , vol.13, no.1, pp.46-51, 2024

TEMİ, Y. B. Et Al. (2024) . "Can the Prognosis be Predicted by the Pretreatment Derived Neutrophil to Lymphocyte Ratio (dNLR) in Patients with Castration-Resistant Prostate Cancer Receiving Enzalutamide?." Kocaeli Tıp Dergisi , vol.13, no.1, pp.46-51.

@article{article, author={YASEMİN BAKKAL TEMİ Et Al. }, title={Can the Prognosis be Predicted by the Pretreatment Derived Neutrophil to Lymphocyte Ratio (dNLR) in Patients with Castration-Resistant Prostate Cancer Receiving Enzalutamide?}, journal={Kocaeli Tıp Dergisi}, year=2024, pages={46-51} }